Question
Does a booster dose provide clinical benefit against symptomatic infection and serious illness due to COVID-19 in persons 60 years and older who are fully vaccinated with the Pfizer-BioNTech vaccine?
Conclusion
A booster (third) dose of the BNT162b2 mRNA vaccine from Pfizer-BioNTech provides significant additional protection against both infection and serious illness. (LOE = 2b)
Recent Posts
- Fluvoxamine decreases hospitalizations in high-risk adults with COVID-19 (TOGETHER)
- Booster with Pfizer mRNA vaccine significantly reduces likelihood of infection and severe illness due to COVID-19 in adults 60+
- Evidence of benefit is lacking for low back pain relief with muscle relaxants
- Recurrent herpes zoster more common in women, younger adults, and the immunosuppressed
- There is limited data on ivermectin in patients with COVID-19